Business Context and Reporting Period
Company: RCM Technologies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: January 31, 1996
Business Overview: RCM Technologies operates through subsidiaries including Intertec Design, Inc. and Cataract, Inc., providing information technology and health care personnel services. The company is pursuing an aggressive acquisition strategy.
Key Financial Metrics
| Metric | Q1 1996 (Unaudited) | Q1 1995 (Unaudited) |
|---|---|---|
| Revenues | $9,776,507 | $6,692,756 |
| Net Income | $501,863 | $229,015 |
| Net Income Per Share | $0.03 | $0.02 |
| Operating Cash Flow | $386,938 | $255,214 |
| Cash and Equivalents (End of Period) | $127,704 | $2,722,059 |
| Working Capital | $3,846,639 | $3,347,994 (Calculated) |
| Bank Debt (Current) | $424,639 | $914,435 |
| Long-Term Debt | $20,090 | $0 |
Margins: Gross profit margin improved to 18.32% in 1996 from 17.2% in 1995. Net income margin was approximately 5.1% in 1996 compared to 3.4% in 1995.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased by $3,088,751 (46.1%) primarily due to the acquisition of Cataract, Inc. in August 1995.
- Profitability: Net income increased by 119.1% to $501,863. This was driven by the elimination of duplicate operating costs and spreading fixed expenses over a larger revenue base.
- Debt Reduction: Outstanding borrowings under the credit facility decreased by $489,796 to $424,639.
- Cash Position: Cash and cash equivalents decreased by $169,846 during the quarter, largely due to net repayments of short-term debt ($489,796) and long-term debt ($28,890).
- Expenses: Cost of services rose 44.1% in line with sales. Selling, general, and administrative (SG&A) expenses increased 29.4% but declined as a percentage of revenue from 13.2% to 11.7% due to operational efficiencies.
Guidance, Outlook, and Risks
Acquisition Activity
- Pending Acquisition: On March 1, 1996, the company entered into an agreement to acquire The Consortium Inc., a provider of IT and health care personnel with over $26 million in 1995 revenues. The deal involves issuing 6.5 million shares of common stock and assuming approximately $1.3 million in bank indebtedness. Closing is anticipated for March 11, 1996, subject to due diligence and approvals.
- Private Placement: On February 5, 1996, the company sold 1,383,125 shares to Limeport Investments, L.L.C. for $1,000,000.
Liquidity and Capital Resources
The company maintains a $6,000,000 credit facility expiring June 30, 1998, with $3,240,246 available as of January 31, 1996. Management believes current resources are sufficient for the next twelve months, though future liquidity may be impacted by the Consortium acquisition.
Risks and Contingencies
- Acquisition Risks: The Consortium transaction is contingent on satisfactory due diligence and regulatory approvals. No assurances are provided regarding the realization of anticipated synergies or profitability enhancements.
- Debt Covenants: The credit facility requires subsidiaries to meet specific financial ratios and earnings objectives.
- Legal Proceedings: No material legal proceedings are currently pending.
Investor Verification Checklist
- Verify the closing status and terms of the pending acquisition of The Consortium Inc., including the assumption of $1.3 million in debt.
- Confirm the impact of the 6.5 million share issuance for the Consortium deal on future earnings per share dilution.
- Review the company's ability to meet financial covenants on its $6 million credit facility following the acquisition.
- Monitor the integration of Cataract, Inc. and the realization of projected operational efficiencies.
- Assess the sustainability of the 18.32% gross margin in the context of future pricing and cost structures.